Live Analyst Rating Changes 54325 upgrades, downgrades & price-target moves Β· freshest Wall Street data, updated daily View live feed β†’
Analyst Tracker/Kristen Kluska
CANT

Kristen Kluska

Wall Street Analyst
β˜…β˜†β˜†β˜†β˜†
#3072
on 13Foresight Β· ranked by our own returns
36%
Success Rate
-5.3%
Average Return
32 of 89 calls profitable Β· -9.7% vs benchmark
S&P 500 (SPY)
πŸ“ˆ Across the calls we could measure, roughly 36% of Kristen Kluska's ratings turned a profit when each position was held for 1 year β€” averaging -5.3% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

128 Buy 20 Hold 0 Sell
Kristen's Stock Coverage 50 ratings Β· 2026-11-17
Company Date Position Consensus β“˜ Price Target β“˜ 1-Yr Return vs S&P 500 β“˜
KARD
Kardigan, Inc.
Oct 29, 2026 BUY Strong Buy
+203.3% avg upside
7 analysts
$50.00
253.87% Upside
-7.8% Β·
PTCT
PTC Therapeutics
Oct 29, 2026 BUY Buy
+35.4% avg upside
29 analysts
$137.00
128.38% Upside
-6.4% Β·
SPRO
Spero Therapeutics
Oct 28, 2026 BUY Buy
+1102.8% avg upside
13 analysts
$6.00
466.05% Upside
-23.1% Β·
DBVT
DBV Technologies SA - American
Oct 28, 2026 BUY Buy
+143.7% avg upside
15 analysts
$48.00
405.71% Upside
-6.2% Β·
MYRG
MYR Group
Oct 28, 2026 BUY Buy
+13.3% avg upside
15 analysts
$441.00
56.05% Upside
-4.5% Β·
PHAT
Phathom Pharmaceuticals
Oct 23, 2026 BUY Strong Buy
+316.5% avg upside
15 analysts
β€” -4.2% Β·
LXEO
Lexeo Therapeutics, Inc.
Oct 21, 2026 BUY Strong Buy
+528.2% avg upside
11 analysts
$23.00
632.48% Upside
-4.7% Β·
IRON
Disc Medicine
Oct 19, 2026 BUY Strong Buy
+23.5% avg upside
21 analysts
$170.00
110.34% Upside
-3.0% Β·
RNA
Atrium Therapeutics, Inc.
Oct 14, 2026 BUY Strong Buy
+246.6% avg upside
6 analysts
$25.00
202.27% Upside
-15.6% Β·
CLDX
Celldex
Oct 13, 2026 BUY Strong Buy
+43.0% avg upside
28 analysts
$72.00
139.19% Upside
-0.8% Β·
TSE:EPRX
Eupraxia Pharmaceuticals
Oct 07, 2026 BUY Strong Buy
+122.3% avg upside
11 analysts
$26.55
178.97% Upside
-4.3% Β·
SE:EGTX
Egetis Therapeutics AB
Sep 29, 2026 BUY Strong Buy
+228.0% avg upside
1 analyst
$33.00
228.03% Upside
+25.5% Β·
RARE
Ultragenyx Pharmaceutical
Sep 17, 2026 BUY Strong Buy
+193.8% avg upside
36 analysts
$39.00
142.23% Upside
+15.2% Β·
MREO
Mereo Biopharma Group Plc
Sep 17, 2026 BUY Strong Buy
+1238.5% avg upside
11 analysts
$3.00
936.21% Upside
-6.9% Β·
ABEO
Abeona Therapeutics
Sep 17, 2026 BUY Strong Buy
+295.1% avg upside
18 analysts
$30.00
589.67% Upside
-53.5% Β·
SLDB
Solid Biosciences
Sep 15, 2026 BUY Strong Buy
+176.4% avg upside
26 analysts
$26.00
319.39% Upside
-25.6% Β·
CAPR
Capricor Therapeutics
Aug 14, 2026 BUY Strong Buy
+332.5% avg upside
12 analysts
$28.00
338.86% Upside
+26.5% Β·
MNPR
Monopar Therapeutics Inc
Aug 12, 2026 HOLD Strong Buy
+51.0% avg upside
18 analysts
$119.00
69.27% Upside
-38.1% Β·
CDXS
Codexis
Aug 11, 2026 BUY Strong Buy
+746.4% avg upside
13 analysts
$11.00
824.45% Upside
-27.7% Β·
TSHA
Taysha Gene Therapies
Aug 11, 2026 BUY Strong Buy
+241.9% avg upside
22 analysts
$19.00
359.98% Upside
-40.1% Β·
RNAC
Cartesian Therapeutics
Aug 06, 2026 BUY Strong Buy
+378.5% avg upside
19 analysts
$16.00
146.61% Upside
-21.3% Β·
ADMA
ADMA Biologics
Aug 05, 2026 HOLD Strong Buy
-3.8% avg upside
15 analysts
$12.00
5.12% Upside
+47.2% Β·
ZVRA
Zevra Therapeutics
Aug 05, 2026 BUY Strong Buy
+113.0% avg upside
15 analysts
$25.00
143.09% Upside
-10.7% Β·
SRPT
Sarepta Therapeutics
Aug 05, 2026 HOLD Buy
+223.8% avg upside
50 analysts
$21.00
12.82% Upside
+0.7% Β·
RIGL
Rigel
Aug 04, 2026 HOLD Strong Buy
-47.4% avg upside
17 analysts
$43.00
16.10% Downside
+10.9% Β·
SUPN
Supernus Pharmaceuticals
Jul 09, 2026 BUY Strong Buy
+30.3% avg upside
9 analysts
$67.00
59.90% Upside
-7.9% Β·
AQST
Aquestive Therapeutics
Jun 25, 2026 BUY Strong Buy
+131.4% avg upside
10 analysts
$11.00
182.74% Upside
-17.2% Β·
QURE
uniQure
Jun 17, 2026 BUY Strong Buy
+121.1% avg upside
30 analysts
β€” -56.9% Β·
FULC
Fulcrum Therapeutics
Mar 19, 2026 BUY Hold
+169.6% avg upside
14 analysts
$24.00
546.87% Upside
-46.7% Β·
SKYE
Skye Bioscience
Mar 10, 2026 HOLD Strong Buy
+3616.0% avg upside
9 analysts
$16.00
1149.91% Upside
-84.4% Β·
XFOR
X4 Pharmaceuticals
Nov 21, 2025 BUY Strong Buy
+613.0% avg upside
16 analysts
$14.00
317.93% Upside
-17.6% Β·
HUMA
Humacyte
Jul 01, 2024 BUY Strong Buy
+1468.9% avg upside
11 analysts
$7.00
1602.28% Upside
-57.5% Β·
IRD
Opus Genetics
May 13, 2024 BUY Strong Buy
+231.4% avg upside
25 analysts
β€” -42.9% Β·
LCTX
Lineage Therap
Feb 04, 2024 BUY Strong Buy
+453.8% avg upside
16 analysts
$6.00
500.07% Upside
-36.5% Β·
OTLK
Outlook Therapeutics
Aug 30, 2023 HOLD Buy
+1882.0% avg upside
11 analysts
$20.00
4172.62% Upside
+36.6% Β·
DRTS
Alpha Tau
Aug 28, 2023 BUY Strong Buy
+7.2% avg upside
5 analysts
$23.00
76.10% Upside
-30.1% Β·
ATNM
Actinium Pharmaceuticals
Jun 28, 2023 BUY Strong Buy
+364.2% avg upside
11 analysts
$27.00
1724.33% Upside
+0.5% Β·
DMRA
Damora Therapeutics
Jun 26, 2023 BUY Strong Buy
+39.9% avg upside
20 analysts
$17.00
20.84% Downside
-80.6% Β·
CMMB
Chemomab Therapeutics
Jun 09, 2023 HOLD Strong Buy
+2244.8% avg upside
6 analysts
β€” -41.7% Β·
HEPA
Hepion Pharmaceuticals
May 15, 2023 BUY Strong Buy
+27281.0% avg upside
9 analysts
$28.00
15455.62% Upside
Β· Β·
EVLO
Evelo Biosciences
Mar 16, 2023 HOLD Buy
+44999900.0% avg upside
5 analysts
$20.00
19999900.06% Upside
Β· Β·
HTGMQ
HTG Molecular Diagnostics
Mar 10, 2023 HOLD Strong Buy
+733333233.3% avg upside
6 analysts
β€” Β· Β·
HLSQ
Tessera Defense and Homeland Security
Mar 10, 2023 HOLD Buy
+14451.8% avg upside
4 analysts
β€” Β· Β·
IBIO
Ibio
Dec 21, 2022 HOLD Strong Buy
+672.4% avg upside
13 analysts
$10.00
1200.91% Upside
-84.8% Β·
EOCN
Eocene
Aug 04, 2022 HOLD Buy
+688.3% avg upside
13 analysts
$10.50
238.67% Upside
Β· Β·
ERNA
Eterna Therapeutics
Dec 29, 2021 BUY Strong Buy
+3554.9% avg upside
4 analysts
$180.00
9037.12% Upside
Β· Β·
OCGN
Ocugen
Sep 28, 2021 HOLD Strong Buy
+1211.8% avg upside
17 analysts
$4.00
469.18% Upside
-71.6% Β·
MBIO
Mustang Bio
May 12, 2021 BUY Strong Buy
+1587.1% avg upside
5 analysts
$10.00
2399.45% Upside
Β· Β·
SCPX
Scorpius Holdings
Mar 02, 2021 BUY Strong Buy
+3051983.3% avg upside
11 analysts
$22.00
3666566.58% Upside
Β· Β·
EVGN
Evogene
Nov 30, 2020 BUY Strong Buy
+2798.7% avg upside
6 analysts
$9.00
2302.55% Upside
Β· Β·
πŸ”’ 45 more ratings β€” with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Kristen Kluska β€” Frequently Asked Questions
How accurate are Kristen Kluska's stock ratings?
Based on the calls 13Foresight could measure, about 36% of Kristen's ratings were profitable over a one-year hold, with an average return of -5.3% per rating, or -9.7% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Kristen ranked on 13Foresight?
Kristen Kluska is currently ranked #3072 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge β€” so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Kristen cover?
Kristen most recently has ratings on KARD, PTCT, SPRO, DBVT, MYRG, PHAT, LXEO, IRON, RNA, CLDX, TSE:EPRX, SE:EGTX and 38 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.